Pharmaceuticals, Biotechnology and Life Sciences
United States Foodand Drug Administration (FDA) has cleared the Company’s lead productcandidate, PLENITY (Gelesis100), as an aid in weight management inadults with a Body Mass Index (BMI) of 25–40 kg/m2, when usedin conjunction with diet and exercise.
BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)…
PureTech Health’s affiliate Gelesis has rasied $30 million to back bringing closer to shelves its pipeline of additinoal gastrointestinal disorders product candidates,…
Gelesis, focused on developing first-in-class products to safely induce weight loss and improve glycaemic control, has presented new data for its second product candidate, Gelesis200